Table 1.
TFE3, TFEB and MITF gene fusions.
| Neoplasm | Fusion | Translocation | Age range (year) |
|---|---|---|---|
| ASPS | ASPSCR1–TFE3 | der(17)(X;17)(p11.2q25) | 1–71 |
| RCC | ASPSCR1–TFE3 | t(X;17)(p11.2;q25) | 1–75 |
| RCC | PRCC–TFE3 | t(X;1)(p11.2;q21) | 2–69 |
| RCC | SFPQ–TFE3 | t(X;1)(p11.2;q34) | 3–68 |
| RCC | NonO–TFE3 | inv(X)(p11.2;q12) | 39 |
| RCC | CLTC–TFE3 | t(X;17)(p11.2;q23) | 14 |
| RCC | LUC7L3–TFE3 | t(X;17)(p11.2;q21) | 20 F |
| RCC | KHSRP–TFE3 | t(X;19)(p11.2;p13) | |
| RCC | PARP14–TFE3 | t(X;3)(p11.2;q23) | 45 F |
| RCC | DVL2–TFE3 | t(X;17)(p11.2;p13.1) | 73 M |
| RCC | RBM10–TFE3 | Inv(X)(p11.2;p11.23) | 32–61 |
| RCC | GRIPAP1–TFE3 | inv(X)(p11.23,p11.23) | 40 F |
| RCC | MED15–TFE3 | t(X;22)(p11.2;q11.2) | 34 F |
| RCC | Unknown | t(X;3)(p11.2;q23) | 32 |
| RCC | Unknown | t(X;10)(p11.2;q23) | 77 |
| Melanotic Xp11 translocation cancer | SFPQ(PSF)–TFE3 | t(X;1)(p11.2;q34) | 11–55 |
| ARID1B–TFE3 | T(X:6)(p11.2;q25.3) | ||
| Melanotic t(6;11) renal cell carcinoma | MALAT1(Alpha)–TFEB | t(6;11)(p21;q12) | |
| Xp11 PEComa | SFPQ–TFE3 and others | t(X;1)(p11.2;q34) and others | 9–55 |
| Subset of epithelioid hemangioendothelioma | YAP1–TFE3 | t(X;11)(p11.2;q13) | 14–50 |
| RCC | MALAT1(Alpha)–TFEB | t(6;11)(p21;q12) | 3–68 |
| RCC | CLTC–TFEB | t(6;17)(p21;q23) | |
| RCC | KHDRBS2–TFEB | inv(6)(p21q11) | |
| RCC | COL21A1–TFEB | inv(6)(p21p12) | |
| RCC | TFEB–CADM2 | t(3;6)(p12;p21) | |
| RCC | ACTG1–MITF | t(17;3)(q25.3;p13) | |
| RCC | PRCC–MITF | t(1;3)(q21;p13) | 45 |
ASPS, alveolar soft part sarcoma; PEComa, perivascular epithelioid cell neoplasm; RCC, renal cell carcinoma; F, female; M, male.